# Complication rates after chorionic villus sampling and midtrimester amniocentesis 

Hsu WW, Hsieh CC, Lee CN, Lin SY<br>National Taiwan Uiversity Hospital, Taipei, Taiwan

## Objective

To assess the complication rates following chorionic villus sampling (CVS) and midtrimester amniocentesis in Taiwan.

## Methods

This is a national registry-based cohort study from Taiwan. We included all singleton pregnant women who underwent CVS ( $n=1,438$ ) or amniocentesis ( $n=255,727$ ) during the years 2006-2012. We assessed preterm premature rupture of membranes (PPROM), intrauterine fetal demise (IUFD), infection and spontaneous abortion (SA) that occurred within 14 days after the procedures. We also assessed the risk of miscarriage before 24 gestational weeks and preterm delivery after amniocentesis. These complications were collected from the Genetic Disease Database (GDD) of the Ministry of Health and Welfare, Taiwan National Birth Certificate Registry, and the Taiwan National Health Insurance Database (NHID). Pearson x2 tests were used to compare distributions between groups.

## Results

For patients who underwent midtrimester amniocentesis, the rates of PPROM, IUFD, infection and SA within 14 days were $0.24 \%, 0.11 \%, 0.05 \%$, and $0.05 \%$, respectively. Women with a normal fetal karyotype had a preterm birth rate of 9. $38 \%$. The miscarriage rate was $0.68 \%$, which was $0.22 \%$ higher than those who did not receive invasive procedures ( $\mathrm{p}<0.0001$ ). After CVS, the IUFD rate was $1.68 \%$, and the SA rate within 14 days was $0.77 \%$.

## Conclusion

A review of recent studies and the use of our large cohort demonstrated that the procedure-related complication rates might not be as high as previously recognized. The low complication rates in our cohort might facilitate counselling in women who consider invasive genetic diagnostic procedures.

Table 1. Complication rates after invasive procedures.

| Complications | Amniocentesis |  |  | CVS |  |
| :--- | :--- | :--- | :--- | :--- | :---: |
|  | $\mathbf{N}$ | $\%$ | $\mathbf{N}$ | $\%$ |  |
| Total number | 250566 | 100.0 | 1409 | 100.0 |  |
| PPROM |  | $\mathbf{0 . 2 5}$ |  |  |  |
| 0-7 days | 446 | 0.18 | $<2$ | $<0.1 \%$ |  |
| 8-14 days |  | 0.07 | $<2$ | $<0.1 \%$ |  |
| IUFD | 125 | $\mathbf{0 . 1 1}$ |  | $\mathbf{1 . 7 0}$ |  |
| 0-7 days | 141 | 0.05 | 11 | 0.78 |  |
| 8-14 days |  | 0.06 | 13 | 0.92 |  |
| Infection | 105 | 0.05 |  |  |  |
| 0-7 days | 27 | 0.04 | $<2$ | $<0.1 \%$ |  |
| 8-14 days |  | $\mathbf{0 . 0 5}$ | $<2$ | $<0.1 \%$ |  |
| Spontaneous abortion | 82 | 0.03 | 7 | $\mathbf{0 . 7 8}$ |  |
| 0-7 days | 48 | 0.02 | 4 | 0.50 |  |
| 8-14 days |  |  |  | 0.28 |  |

CVS = chorionic villus sampling, PPROM = preterm premature rupture of membranes, IUFD = intrauterine fetal demise

Table 2. Pregnancy outcomes of subjects with and without invasive procedures.

| Birth Outcome | No invasive <br> procedures |  |  | Amniocentesis ( $\geq 15$ weeks) |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total | \% | Total | $\%$ | P value | Normal karyotype | \% | P value |  |  |
| Number | 1134403 |  | 231564 |  |  | 220399 |  |  |  |  |
| Gestational age (weeks) |  |  |  |  | $<0.0001$ |  | 1493 | 0.68 |  |  |
| $<24$ (miscarriage) | 5205 | 0.46 | 3449 | 1.49 | $<0.0001$ | $<0.0001$ |  |  |  |  |
| $24-33$ | 14918 | 1.32 | 4982 | 2.15 |  | 4586 | 2.08 |  |  |  |
| $34-36$ | 64886 | 5.72 | 15233 | 6.58 |  | 14591 | 6.62 |  |  |  |
| $\geq 37$ | 1049382 | 92.51 | 207899 | 89.78 |  | 199728 | 90.62 |  |  |  |
| Preterm | 85009 | 7.50 | 23664 | 10.22 | $<0.0001$ | 20670 | 9.38 | $<0.0001$ |  |  |

Table 3. Review of studies on procedure-related fetal loss after amniocentesis.

| Study (y) | Study interval | Study design | Amniocentesis | Definition of pregnancy loss | Spontaneous fetal loss rate | Control group | Procedurerelated risk |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Tabor et al | 1982-1984 | RCT | 2302 | 24 weeks | 1.26 | 0.17 | 1.09 |
| CEMAT group (1998) | 1994-1996 | RCT | 2162 | 20 weeks | 0.78 |  |  |
| Borrell et al (1999) |  | RCT | 358 | In 14 days/ 20/28 weeks | 0.8/0.6/0.3 |  |  |
| Seeds et al (2004) | 1984-2002 | Review | 34144 | 28 weeks | 1.4 | 1.08 | 0.32 |
| Eddleman et al (2006) | 1999-2002 | Case-control | 3096 | 24 weeks | 1 | 0.94 | 0.06 |
| Kong et al (2006) | 1997-2004 | Cohort | 3468 | Before birth | 1.66 | 0.8 | 0.86 |
| Mujezinovic et al (2007) | 1995-2006 | Review | 49413 | In 14 days/24 weeks | 0.6/0.9 |  | 0.6 |
| Odibo et al (2008) | 1990-2006 | Cohort | 11746 | 24 weeks | 0.97 | 0.84 | 0.13 |
| Tabor et al (2009) | 1996-2006 | Cohort | 32852 | 24 weeks | 1.4 |  |  |
| Pitukkijronnakorn et al (2011) | 1997-2006 | Case-control | 2990 | 24/28 weeks | 0.37/1.37 | 0.2/0.87 | 0.17/0.5 |
| Akolekar et al (2015) | 2000-2014 | Meta-analysis | 42716 | 24 weeks | 0.81 | 0.67 | 0.11 |
| Hsu et al (our data) | 2006-2012 | Cohort | 220399 | 24 weeks | 0.68 | 0.46 | 0.22 |

